This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_LUNG_NEUROENDO_EXALLC for full statistics.
Neuroendocrine tumor and carcinoma of lung
C3_LUNG_NEUROENDO
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Cancer registry: Topography ICD-O-3
C34
Cancer registry: Morphology ICD-O-3
8240|8246|8249
Cancer registry: Behaviour codes
3
1 out of 7 registries used, show all original rules.
180
Check minimum number of events None
180
Include endpoints None
180
Remove individuals based on genotype QC
177
C3_LUNG_NEUROENDO
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Neuroendocrine tumor and carcinoma of lung
based on the number of shared cases.
Broader endpoints:
- Neuroendocrine tumor and carcinoma of lung (controls excluding all cancers)
- Malignant neoplasm of bronchus and lung (controls excluding all cancers)
- Malignant neoplasm of bronchus and lung
- Malignant neoplasm of respiratory system and intrathoracic organs
- Malignant neoplasm of respiratory system and intrathoracic organs (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 177 | 103 | 74 |
| Unadjusted prevalence (%) | 0.04 | 0.04 | 0.04 |
| Mean age at first event (years) | 61.30 | 59.40 | 63.94 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_LUNG_NEUROENDO – Neuroendocrine tumor and carcinoma of lung
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Neuroendocrine tumor and carcinoma of lung
↥Endpoint not on priority list, no data to show.